Analytical Data
-
基因名
PSCA
-
简介
PSCA protein is a multifunctional regulator that may modulate cell proliferation and act as a modulator of nicotinic acetylcholine receptor (nAChR) activity. In vitro experiments showed that it can inhibit nicotine-induced signaling, suggesting interaction with nAChR containing α-3:β-2 or α-7. PSCA Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PSCA protein, expressed by HEK293 , with N-hFc labeled tag.
- Application
-
别名
PSCA; UNQ206; PRO232
-
种属
Mouse
-
表达系统
HEK293
-
标签
N-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P57096
-
表达区间
L21-N95
-
蛋白长度
Full Length of Mature Protein
-
分子量
40-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of PSCA (Prostate Stem Cell Antigen) recombinant proteins is rooted in the significant role that PSCA plays in prostate cancer biology and its potential as a therapeutic target. PSCA is a glycosylphosphatidylinositol-anchored membrane protein that is overexpressed in various malignancies, particularly prostate cancer, making it an attractive candidate for cancer immunotherapy. Research has shown that high levels of PSCA correlate with tumor progression and poor prognosis, highlighting its importance in cancer diagnostics and treatment strategies. Recombinant protein technology allows for the production of large quantities of PSCA, facilitating the exploration of its functional properties, immunogenicity, and potential as a target for monoclonal antibody development. By creating recombinant PSCA proteins, researchers can conduct detailed studies on their structure and interaction with immune cells, paving the way for vaccine development aimed at eliciting an immune response against PSCA-expressing tumors. Furthermore, the understanding of PSCA's mechanisms of action can lead to the identification of novel biomarkers and therapeutic approaches, ultimately contributing to improved management of prostate cancer and other PSCA-associated malignancies.
